2017
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
Pease AM, Krumholz HM, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. The BMJ 2017, 357: j1680. PMID: 28468750, PMCID: PMC5421452, DOI: 10.1136/bmj.j1680.Peer-Reviewed Original ResearchMeSH KeywordsControlled Clinical Trials as TopicDrug ApprovalHumansProduct Surveillance, PostmarketingUnited StatesUnited States Food and Drug AdministrationConceptsSingle pivotal trialPivotal trialsPostapproval studiesSurrogate markerPrimary endpointNovel drugsClinical outcomesClinical studiesLimited evidenceSystematic reviewDouble-blind studyMedian total numberClinical evidenceSuperior efficacyBlind studyDrug AdministrationOriginal FDATrial approvalDiseaseTrialsDrugsFDAEndpointEfficacyMarkers
1997
Determinants of Appropriate Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction in Persons ≥65 Years of Age
Krumholz H, Vaccarino V, Ellerbeck E, Kiefe C, Hennen J, Kresowik T, Gold J, Jencks S, Radford M. Determinants of Appropriate Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction in Persons ≥65 Years of Age. The American Journal Of Cardiology 1997, 79: 581-586. PMID: 9068512, DOI: 10.1016/s0002-9149(96)00819-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlabamaAngiotensin-Converting Enzyme InhibitorsConnecticutContraindicationsControlled Clinical Trials as TopicDecision MakingDiabetes ComplicationsDiureticsDrug PrescriptionsDrug UtilizationFemaleFollow-Up StudiesHeart FailureHospitalizationHumansIowaMaleMedicaidMultivariate AnalysisMyocardial InfarctionPatient DischargeRetrospective StudiesStroke VolumeTachycardia, VentricularUnited StatesVentricular Function, LeftWisconsinConceptsAcute myocardial infarctionACE inhibitorsMyocardial infarctionDischarge medicationsVentricular functionEnzyme inhibitorsLeft ventricular ejection fractionAngiotensin-converting enzyme inhibitorAngiotensin converting enzyme (ACE) inhibitorsVentricular Enlargement (SAVE) trialCongestive heart failureVentricular ejection fractionYears of ageEligible patientsPatient characteristicsAppropriate patientsDiabetes mellitusEjection fractionHeart failureLoop diureticsMultivariable analysisVentricular tachycardiaIdeal patientObservational studyPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply